Cure8 news brief
Company-reported one-year results suggest mirikizumab (Omvoh), an IL-23p19 inhibitor, can achieve multi-dimensional treatment goals including symptom control, quality-of-life improvement, and steroid-free deep remission in some patients with UC and Crohn’s disease — including those with prior biologic failure.
Adult patients with ulcerative colitis or Crohn’s disease (including those with prior biologic failure), clinicians treating IBD, and people following new biologic therapies and combination trials.
The article summarizes analyses from Lilly’s LUCENT (ulcerative colitis) and VIVID (Crohn’s disease) clinical programs. In UC, 27.7% of patients on mirikizumab reached the composite comprehensive-control endpoint at one year versus 14% with placebo; among those with prior biologic failure the rates were 23.4% versus 9.4%.
In Crohn’s, 20.4% on mirikizumab achieved corticosteroid-free deep remission at one year versus 2% on placebo, with 15.7% versus 0% in the prior-biologic-failure subgroup. The article also notes improvements in quality-of-life scores and reduced bowel urgency for responders.
The reporting is based on company-released trial program analyses and highlights ongoing combination studies testing mirikizumab with other agents and in patients with obesity. This summary reflects the company’s reported findings; it does not substitute for full trial publications, regulatory documents, or clinical guidance.
These results are reported by Eli Lilly from the LUCENT and VIVID clinical programs and summarized in a business news piece. Full peer-reviewed publications, regulatory review documents, or independent analyses would provide more complete information on study design, statistical robustness, safety, and applicability to individual patients.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
These results suggest mirikizumab can achieve multiple treatment goals at once — symptoms, objective inflammation measures, and steroid-free status — outcomes that matter to people with IBD because they reflect both...
A new FDA-approved biologic option (Omvoh/mirikizumab) is now available for adults with moderately to severely active Crohn’s disease, potentially expanding treatment choices.
A newly approved biologic, Omvoh (mirikizumab), gives another FDA‑approved treatment option for adults with moderate to severe Crohn’s disease and adds to Lilly’s role in IBD care.
